DOCSLIB.ORG

A ABPA, 69, 71 Acinus-Terminal Respiratory Unit, 8 Acute

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A ABPA, 69, 71 Acinus-Terminal Respiratory Unit, 8 Acute Index A — in microscopic polyangiitis, 143 — asbestosis, 99 ABPA, 69, 71 — p-ANCA, 143, 144, 147, 148 — BOOP, 57, 59 Acinus-terminal respiratory unit, 8 —— in Wegener granulomatosis, 135, 136, 139 — cell profiles, 16 Acute hypersensitive pneumonitis, ground- Anti Scl-70 antibodies, 113, 115 — CEP, 72 glass attenuation, 22 Anti-GBM disease see Goodpasture disease — Crohn disease, 196 Acute interstitial pneumonia (AIP), 4, 37, Anti-GMB antibodies, 135 — CSS, 147, 150 61–63 Anti–GM-CSF autoantibodies, 167 — DIP, 47 — clinical conditions associated, 62 Antimoniosis, 101 — drug-induced lung diseases, 75, 77 — diagnosis procedure, 61, 63 Anti-neutrophil cytoplasmic autoantibodies — hypersensitivity pneumonitis, 95 — histopathological findings, 61, 62 see ANCAs — idiopathic pulmonary fibrosis, 43 — lung lavage cell profiles, 16 Anti-nuclear antibodies (ANA), in SLE, 119, — in IIP diagnosis, 38–39 — pathogenesis, 61 120, 121 — IPF, 43 — symptoms, 61 Antiphospholipid syndrome, 123 — IPH, 159, 162 — therapy, 63 ARDS see acute respiratory distress syndrome — Langerhans cell histiocytosis, 177 Acute lupus pneumonitis, 119 Asbestosis, 97, 99 — LIP, 65 Acute respiratory distress syndrome (ARDS), — malignant mesothelioma with, 201 — NSIP, 52 in pancreatitis, 193, 194 Asthma, heroin-related, 85 — PAM, 163 Acute silicoproteinosis, 97 — PAP, 167, 168, 169 AIP see acute interstitial pneumonia B — RB-ILD, 47, 49 Airway obstruction, interstitial lung disease BAL see bronchoalveolar lavage — rheumatoid arthritis, 110 and, 12, 15 Ball, R., 107 — Sjögren syndrome, 129 Allergic bronchopulmonary aspergillosis BALT see bronchus associated lymphoid tissue — SLE, 123 (ABPA), 69, 71 Baritosis, 101 — systemic sclerosis, 113 Alpha heavy-chain disease, 187 Behçet disease (BD), 155, 156–157 — Wegener granulomatosis, 139 Alpha-1 antitrypsin deficiency, 190 — pathology, 155, 157 Bronchocentric granulomatosis, 69 Alveolar cell carcinoma, 199 — symptoms, 155, 156 Bronchoscopy Alveolar cell hyperplasia, 199 — treatment, 155 — IPH, 159, 162 Alveolar hemorrhage, cocaine-induced, 88 Benign pneumoconiosis, 101 — sarcoidosis, 35 Alveolar lymphocytosis, in Crohn disease, 196 Berylliosis, 101 — Wegener granulomatosis, 137, 138, 139 Alveolar macrophages, 10 Bilateral hilar adenopathy (BHL), in Bronchus associated lymphoid tissue (BALT), Alveolar proteinosis, lung lavage cell profiles, sarcoidosis, 32 proliferations, 65 16 Bioactivation, of xenobiotics, 75, 76 Alveolar walls, 8 Biotransformation, 75, 76 C Alveolocapillary membrane, 8 Biperidine, interstitial reactions, 78 Calcinosis, in multiple myeloma, 186 Amiodarone BOOP see bronchiolitis obliterans organizing Cancer, in interstitial lung disease, 199–202 — cytological appearance of exposure, 77 pneumonia Cannabis, 86 — lung toxicity, 76–77 Breast cancer, 199 Caplan syndrome, large nodules in, 21 Ammonium, effects, 104 Bronchiolitis obliterans interstitial pneumonia Cardiac sarcoidosis, 25, 29, 36 Amyloidosis, 181–185 (BIP), 3 Carrington, C. B., 65 — diagnosis, 182–183, 185 Bronchiolitis obliterans organizing pneumonia Cavitary lung diseases, causes, 173 — diffuse alveolar, 182 (BOOP), 4, 37, 57–59 Celiac disease, 159 — hilar adenopathy in, 182, 184 — clinical conditions associated, 58 Central peribronchovascular thickening, 20 — mediastinal, 182 — as cliniopathologic entity, 57 CEP see chronic eosinophilic pneumonia — parenchymal nodules, 181–182 — cocaine-induced, 88 Charcot, J. M., 1, 3 — pleural involvement, 182, 184 — diagnosis, 57 Chemical pneumonitis, 103–105 — primary, 181 — histopathological finding, 59 — causative agents, 104 — therapy, 183 — Idiopathic Chest radiographs see radiographs — tracheobronchial, 181, 183 — lung lavage cell profiles, 16 Chest roentgenogram see radiographs ANCA-positive vasculitis, cocaine abuse and, — pathogenesis, 57 Chronic airway inflammation, in IBD, 194, 195, 88 — toxic fume-induced, 103 196 ANCAs — treatment, 59 Chronic eosinophilic pneumonia (CEP), 69, — c-ANCAs, 136, 139 Bronchoalveolar lavage (BAL), 15–16 72 — in CSS, 147, 148 — AIP, 61 Chronic phthisis, fibrosis development in, 2 203 204 Index Chronic pneumonitis, 1 DM see dermatomyositis Heerfordt syndrome, 25 — caused by syphilis, 2 Drug addict’s lung, 85–88 Heliotrope rash, 126 Churg-Strauss syndrome (CSS), 147–150 Drug-induced lung diseases, 75–78 Hemosiderin, 159 — classification, 148 — classification by clinical features, 76 Hepato-pulmonary syndrome, 189 — clinical features, 147, 148 — diagnosis, 75 Heroin, 85, 86 — consolidation in, 22 — history, 75 — acute complications, 85 — diagnosis, 147 — prevalence, 75 — chronic complications, 85, 86, 87 — incidence, 147 — rechallenge test, 75 Heroin-abuser lung, 85 — phases, 147 Drug-induced pneumonitis, lung lavage cell High-intensity lymphocytic alveolitis, in — prognosis, 147 profiles, 16 hypersensitivity pneumonitis, 91, 95 — therapy, 147 Dry eye, 129, 130 High-resolution computed tomography see Cigarette smoking see smoking Dry mouth, 129, 131 HRCT Cirrhosis, hyperventilation and, 189 Dyspnea,7,10 Hilar adenopathy Cirrhosis of the lung, 1 — in amyloidosis, 182, 184 Clubbing, 11 E — in MGUS, 187 — interstitial pneumonitis/fibrosis and, 1 Ellman, P., 107 Hinson, K., 3 — in IPF, 41, 42 Emphysema, 190 Histoplasmosis, 69 Coal miner’s pneumoconiosis, 97, 99 Eosinophilic interstitial lung disease, 69–73 HMB45, 171, 172 Cocaine, 86, 88 — classification, 70 Hoarseness, rheumatoid arthritis-related, 107, Coccidioidomycosis, 69 — clinical conditions associated, 73 109 Connective tissue disease, lung lavage cell Eosinophilic pneumonia, lung lavage cell Honeycombing, 22, 23 profiles, 16 profiles, 16 — in IPF, 22 Consolidation, 22, 23 Erythema nodosum, 11 HP see hypersensitivity pneumonitis — in Churg-Strauss syndrome, 22 Esophageal scleropathy, pulmonary HRCT, 12, 19–23 Corrigan, Dominic, 1, 3 complications, 193 — AIP, 57 Crack, 88 Esophagus disease, in systemic sclerosis, 113, — amyloidosis, 182, 184 CREST syndrome, 113 116, 193, 194 — BOOP, 57, 58, 59 — PBC and, 191 Extrinsic allergic alveolitis see hypersensitivity — CSS, 147, 149 Crohn disease, 196, 197 pneumonitis — DIP, 47, 49 Cryptococcosis, 69 Eyes, in sarcoidosis, 25, 28, 36 — drug-induced lung diseases, 75, 78 Cryptogenic fibrosing alveolitis, 3 — finding in common interstitial lung — see also idiopathic pulmonary fibrosis F diseases, 23 Cryptogenic organizing pneumonia (COP) see Farmer’s lung, 94 — hard-metal pneumoconiosis, 100 bronchiolitis obliterans organizing Fibroblasts, proliferation in IPF, 41 — hypersensitivity pneumonitis, 93, 94 pneumonia Flint, Austin, 1, 3 — IPF, 43, 44 CSS see Churg-Strauss syndrome Flow-volume loops, 14 — IPH, 159, 160, 161 Cutaneous sarcoidosis, 26–27 Flufenazine, interstitial reactions, 78 — LAM, 171, 172, 173 Cystic lung diseases, causes, 173 Fox,Wilson,1,2,3 — Langerhans cell histiocytosis, 175, 176 Cysts, lung see lung cysts Frank, S., 107 — LIP, 65, 66 Cytokines, release, in IPF, 41 — lung cancer, 200 G — lymphangitic carcinomatosis, 202 D Gallium-67 citrate, 19 — migratory radiation pneumonitis, 83 DAD see diffuse alveolar damage Gallium-67 scanning, 19, 20 — NSIP, 51–52, 53, 54 DAH see diffuse alveolar hemorrhage Gamma heavy-chain disease, 187 — PAM, 163, 164 Dermatomyositis (DM), 125–127 Gastric cancers, 201 — PAP, 167, 168 — interstitial lung disease in, 125 Gastroesophageal reflux disease, 193, 194 — PM/DM, 125, 127 — pulmonary manifestations, 125, 126 Gastrointestinal system, lungs and, — pulmonary involvement in rheumatoid — treatment, 125 193–197 arthritis, 107, 109, 110 Desquamative interstitial pneumonia (DIP), 3, Genital ulcers, in Behçet disease, 155 — PVOD, 155, 158 4, 37, 47–49 Giant cell interstitial pneumonia (GIP), 3 — sarcoidosis, 33 — clinical features, 47 — in hard-metal pneumoconiosis, 100 —— vs IPF, 14 — diagnostic procedure, 47 GM-CSF, 167 — Sjögren syndrome, 129, 132 — histopathological findings, 47, 48 Goodpasture disease, 151–153 — SLE, 119, 121, 122 — lung lavage cell profiles, 16 — clinical features, 151, 152 — systemic sclerosis, 113, 117 — RB-ILD vs, 49 — diagnosis, 151 — toxic inhalation injuries, 104, 105 Diamond polisher lung, 100 — histopathology, 151, 152 — Wegener granulomatosis, 137, 138 Diffuse alveolar damage (DAD), 61 — symptoms, 151 Hypercalcemia, in sarcoidosis, 25 — clinical conditions associated, 62 — treatment, 151, 153 Hypercalcuria, in sarcoidosis, 25 Diffuse alveolar hemorrhage (DAH), 39 Ground-glass attenuation, 22, 23 Hypereosinophilic pneumonia, 69 — causes, 160 — in acute hypersensitive pneumonitis, 22 Hypersensitivity pneumonitis (HP), 91–95 — lung lavage cell profiles, 16 — acute, 91, 92 — in microscopic polyangiitis, 143, 145 H — causes, 92 — in SLE, 119, 121 Hamman, Louis, 1, 3, 61 — chronic, 91, 94 — in Wegener granulomatosis, 139 Hamman-Rich syndrome, 3, 4 — clinical diagnosis, 91 Diffuse parenchymal lung disease (DPLD), — see also acute interstitial pneumonia — lung lavage cell profiles, 16 definition, 7 Hard-metal pneumoconiosis, 100 — pathogenetic mechanisms, 91 DIP see desquamative interstitial pneumonia Hashish, 86 — pathologic mechanisms, 91 Dirofilaria, 69, 70 Heavy-chain diseases, 187 — presentation, 91 Index 205 — prevention and management, 95 Interstitial pneumonia, 3 Lung lavage cell profiles, in common — subacute, 91, 93 Interstitial pneumonitis, classification, 3 interstitial lung diseases, 16 Hyperventilation, cirrhosis and, 189 Interstitium, 8 Lung parenchyma Intralobular thickening, in idiopathic — cell types, 10 I pulmonary fibrosis, 21 — structure, 8–10 IBD see inflammatory bowel disease IPF see idiopathic
Load more

Recommended publications
  • MS32-Chun-Red
    Text19/12/2008 MATERIAL SAFETY DATA SHEET PRODUCT / MATERIAL: GLAZE MANUFACTURER / DISTRIBUTOR: LAGUNA CLAY COMPANY ADDRESS: 14400 Lomitas Avenue, City of Industry, CA 91746 PHONE / FAX / EMAIL: (626) 330-0631 / (626) 333-7694 / [email protected] SECTION I - PRODUCT INFORMATION TRADE NAME: MS32 SYNONYM: CHUN RED CHEMICAL FAMILY: Ceramic Blend SECTION II - HAZARDOUS INGREDIENTS Maximum OSHA PEL NIOSH REL ACGIH TLV INGREDIENT NAMEPercent CAS NUMBER TWA: (mg/m3) TWA: (mg/m3) TWA: (mg/m3) Barium or Barium Compounds5 7440-39-3 0.5 0.5 0.5 Calcium Carbonate7 1317-65-3 5 5 10 Lithium Carbonate1 554-13-2 Silica, Crystalline (Quartz)20 14808-60-7 10 mg/m3 / 0.05 0.05 %SiO2 + 2 Silicon Carbide1 409-21-2 15 10 Tin or Tin Compounds2 7440-31-5 2 2 Zinc or Zinc Compounds4 7440-66-6 5 5 5 SECTION III - PHYSICAL DATA BOILING POINT (°F) Not Applicable VAPOR PRESSURE Not Applicable VAPOR DENSITY Not Applicable SOLUBILITY IN WATER Insoluble SPECIFIC GRAVITY 1.7 – 3.7 PERCENT VOLATILE BY WEIGHT 0 EVAPORATION RATE 0 APPEARANCE AND ODOR Color varies between moist and dry state; no odor. SECTION IV - FIRE AND EXPLOSION HAZARD DATA FLASH POINT Not Flammable EXTINGUISHING MEDIA Water UNUSUAL FIRE OR EXPLOSION HAZARDS None SPECIAL FIRE FIGHTING PROCEDURES None SECTION V - REACTIVITY DATA STABILITY FACTOR Product is stable. INCOMPATIBILITY None HAZARDOUS DECOMPOSITION PRODUCTS None. Hazardous polymerization will not occur. CONDITIONS TO AVOID Inhalation of dust. Text10MS32 Text10Page 1 of 3 Text19/12/2008 MATERIAL SAFETY DATA SHEET SECTION VI - HEALTH HAZARD DATA Barium or Barium Compounds Chronic Toxicity: Chronic overexposure may lead to varying degress of paralysis of the extremities.
    [Show full text]
  • An Approach to Interpreting Restrictive Spirometric Pattern Results In
    Med Lav 2016; 107, 6: 419-436 An approach to interpreting restrictive spirometric pattern results in occupational settings Federica Tafuro, Massimo Corradi Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy KEY WORDS Diagnostic algorithm; FEV1; FVC; FEV6; FEV1/FVC; interpretative criteria; lung function testing; occupa- tional exposure PAROLE CHIAVE Algoritmi diagnostici; FEV1; FVC; FEV6; FEV1/FVC; criteri interpretativi; test di funzionalità polmonare; esposizione occupazionale SUMMARY Objectives: The aim of this review is to provide an updated overview of definition, epidemiology, diagnostic algo- rithm and occupational exposures related to abnormal restrictive spirometrical pattern (RSP) in order to improve the correct interpretation of spirometry test results by occupational healthcare providers. Methods: A review of the scien- tific English literature of the last 25 years was carried out with MEDLINE and related keywords [(restricti* AND spirometr*) AND occupational]. The first step analysis covered 40 studies and the second step the reference list. Results are presented in four major aims and subquestions. Results: A spirometrical pattern of reduced VC (Vital Capacity), together with a normal FEV1 (Forced Expiratory Volume in 1 Second)/VC ratio, is suggestive, though not diagnostic of restrictive ventilatory defect (RVD). The prevalence of RSP is high in some studies, comparable to obstructive pat- tern, and could be associated to chronic medical conditions (diabetes, congestive heart failure, obesity, hypertension) as well as to increased risk of mortality and lung cancer. In order to predict true restrictive defect [TLC-(Total Lung Capacity) <LLN (Lower Limit of Normality) gold-standard for diagnosing restrictive lung diseases (RLD)] from spirometrical data, mathematical models have been developed, but more studies in occupational setting are necessary to clarify the accuracy of such approaches in health surveillance programmes.
    [Show full text]
  • CT Findings of High-Attenuation Pulmonary Abnormalities
    Insights Imaging (2010) 1:287–292 DOI 10.1007/s13244-010-0039-2 PICTORIAL REVIEW CT findings of high-attenuation pulmonary abnormalities Naim Ceylan & Selen Bayraktaroglu & Recep Savaş & Hudaver Alper Received: 5 June 2010 /Revised: 10 July 2010 /Accepted: 16 August 2010 /Published online: 4 September 2010 # European Society of Radiology 2010 Abstract features and radiological findings can significantly improve Objectives To review the computed tomography (CT) diagnostic accuracy. findings of common and uncommon high-attenuation pulmonary lesions and to present a classification scheme Keywords Computed tomography. Pulmonary of the various entities that can result in high-attenuation abnormalities . High attenuation . Nodules . Reticular pulmonary abnormalities based on the pattern and distribu- pattern . Consolidation . Extraparenchymal lesions tion of findings on CT. Background High-attenuation pulmonary abnormalities can result from the deposition of calcium or, less commonly, Introduction other high-attenuation material such as talc, amiodarone, iron, tin, mercury and barium sulphate. CT is highly High-attenuation pulmonary abnormalities can result from a sensitive in the detection of areas of abnormally high variety of different conditions, including from the deposi- attenuation in the lung parenchyma, airways, mediastinum tion of calcium. Amiodarone pulmonary toxicity may cause and pleura. The cause of the calcifications and other high- high-attenuation pulmonary parenchymal opacities. Multi- attenuation conditions may be determined based on the ple dense nodular opacities are rarely seen in siderosis, location and pattern of the abnormalities within the lung stannosis, talcosis and baritosis, in which iron, tin, talc and parenchyma and knowledge of the associated clinical barium sulfate respectively are deposited in the lungs.
    [Show full text]
  • Toxicological Profile for Barium and Barium Compounds
    TOXICOLOGICAL PROFILE FOR BARIUM AND BARIUM COMPOUNDS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry August 2007 BARIUM AND BARIUM COMPOUNDS ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. BARIUM AND BARIUM COMPOUNDS iii UPDATE STATEMENT A Toxicological Profile for Barium and Barium Compounds, Draft for Public Comment was released in September 2005. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine/Applied Toxicology Branch 1600 Clifton Road NE Mailstop F-32 Atlanta, Georgia 30333 BARIUM AND BARIUM COMPOUNDS iv This page is intentionally blank. v FOREWORD This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.
    [Show full text]
  • Metal Lithium Physical and Chemical Properties
    Metal Lithium Physical And Chemical Properties UnmerchantableToffee-nosed Jan Loren piffled knobs believably. availably. Gyrose and percoid Ravil never cringe his embroideries! The lithium and metal What patch found however nice that the chemical and physical properties of the. Kay redfield jamison, whereas brine in many surface tension of the metal, the skin lesions differ somewhat protects the lighter. Before the use of molten li on being recovered from toxic effects following is lithium, conjunctivitis and metal lithium and physical properties are the winter snap and possible. Luca Attanasio and form other two die without his UN convoy is attacked near Goma. When placed in contact with less, pure lithium reacts to form lithium hydroxide and her gas. He did each and metal lithium physical properties are brines are packed in. Elemental lithium metal by physical properties? Workers should be educated in possible hazards, and proper engineering controls should be installed during production of microelectronic devices where exposure to gallium arsenide is likely. Articles manufactured air during a chemical properties are very radioactive isotopes are related to keep alkali metals have produced on a material is why is. It reacts with water gives off so visit this? Oxidation: Lithium is extra strong reducing agent and thwart a weak oxidizing agent in contract to other alkali metals. To sky for these repeating trends, Mendeleev grouped the elements in job table that concept both rows and columns. Lithium and Lithium Compounds Wietelmann Major. Chlorine atom new gosling. Corrosiveness, flammability, toxicity, acidity, or chemical reactivity are all examples of chemical properties of matter.
    [Show full text]
  • Information Notices on Occupational Diseases: a Guide to Diagnosis
    K E - 8 0 - 0 9 - 5 3 4 - E N - C Information notices on occupational diseases: a guide to diagnosis Are you interested in the publications of the Directorate-General for Employment, Social Affairs and Equal Opportunities? If so, you can download them at http://ec.europa.eu/employment_social/publications/about_us/index_en.htm or take out a free online subscription at http://ec.europa.eu/employment_social/publications/register/index_en.htm ESmail is the electronic newsletter from the Directorate-General for Employment, Social Affairs and Equal Opportunities. You can subscribe to it online at http://ec.europa.eu/employment_social/emplweb/news/esmail_en.cfm http://ec.europa.eu/social/ European Commission Information notices on occupational diseases: a guide to diagnosis European Commission Directorate-General for Employment, Social Affairs and Equal Opportunities F4 unit Manuscript completed in January 2009 Neither the European Commission nor any person acting on behalf of the Commission may be held responsible for the use that may be made of the information contained in this publication. © Photo cover page Sartorius Stedim Biotech S.A. Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. More information on the European Union is available on the Internet. (http://europa.eu). Cataloguing data can be found at the end of this publication. Luxembourg: Office for Official Publications of the European Communities, 2009 ISBN 978-92-79-11483-0 doi 10.2767/38249 © European Communities, 2009 Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • Pulmonary Alveolar Microlithiasis: No Longer in the Stone Age
    REVIEW PULMONARY ALVEOLAR MICROLITHIASIS Pulmonary alveolar microlithiasis: no longer in the stone age Elisabeth Bendstrup 1 and Åsa Lina M. Jönsson2 Affiliations: 1Center for Rare Lung Diseases, Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark. 2Dept of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark. Correspondence: Elisabeth Bendstrup, Center for Rare Lung Diseases, Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. E-mail: [email protected] ABSTRACT Pulmonary alveolar microlithiasis (PAM) is a rare parenchymal lung disease caused by variants in the SCL34A2 gene and characterised by the accumulation of intra-alveolar microliths. PAM has been reported in fewer than 1100 cases throughout the world. It is an autosomal recessive hereditary disease and often associated with consanguinity. Progress with respect to the genetic background and pathophysiology has resulted in an increased understanding of the disease in recent years. Until now, 30 genetic different SLC34A2 variants have been reported, which all are considered significant for disease development. There is no sex difference and the majority of cases are diagnosed at the age of 30–40 years. Many patients are asymptomatic and the diagnosis is made at random. When symptomatic, dyspnoea, cough, chest pain and fatigue are common complaints. The diagnosis of PAM can confidently be based on typical radiographic findings and genetic testing proving rare biallelic SCL34A2 gene variants. Bronchoalveolar lavage and histopathology may show microliths. There is no disease-specific treatment and management is supportive. Lung transplantation should be considered in advanced cases. @ERSpublications Pulmonary alveolar microlithiasis is a rare, autosomal recessive lung disease.
    [Show full text]
  • Pneumoconioses
    Review Article Pneumoconioses Vinaya S. Karkhanis and J.M. Joshi Department of Pulmonary Medicine, T. N. Medical College and B.Y.L. Nair Hospital, Mumbai, India ABSTRACT Occupational lung diseases are caused or made worse by exposure to harmful substances in the work-place. “Pneumoconiosis” is the term used for the diseases associated with inhalation of mineral dusts. While many of these broad- spectrum substances may be encountered in the general environment, many occur in the work-place for greater amounts as a result of industrial processes; therefore, a range of lung reactions may occur as a result of work-place exposure. Physicians in metropolitan cities are likely to encounter pneumoconiosis for two reasons: (i) patients coming to seek medical help from geographic areas where pneumoconiosis is common, and (ii) pneumoconiosis caused by unregulated small-scale industries that are housed in poorly ventilated sheds within the city. A sound knowledge about the various pneumoconioses and a high index of suspicion are necessary in order to make a diagnosis. Identifying the disease is important not only for treatment of the individual case but also to recognise and prevent similar disease in co-workers. [Indian J Chest Dis Allied Sci 2013;55:25-34] Key words: Pneumoconiosis, Occupation, Fibrosis. INTRODUCTION without such a reaction. Silicosis, coal worker pneumoconiosis, asbestosis, berylliosis and talcosis History of mining goes far back to pre-historic times are examples of fibrotic pneumoconiosis. Siderosis, as far back as ancient Greece and Rome, when men stannosis and baritosis are non-fibrotic forms of mined for salts, flint and ochre.
    [Show full text]
  • Barium Bronchogram Following Aspiration of Contrast: a Case Report
    Journal of Medicine and Medical Sciences Vol. 3(11) pp. 687-691, November 2012 Available online http://www.interesjournals.org/JMMS Copyright © 2012 International Research Journals Case Report Barium bronchogram following aspiration of contrast: a case report Erondu Felix Okechukwu Dept. of Clinical Imaging, Image Diagnostics, Port-Harcourt Nigeria E-mail: [email protected]; Tel: +2348023129893 ABSTRACT Barium swallow remains the simplest most commonly performed examination of the upper GIT, providing both anatomic and functional information about the oropharyngeal and esophageal apparatus. Barium aspiration as a complication of this procedure is not new, but its dynamics and clinical implications continue to evolve. We present a case study involving a 57-year-old Nigerian male who was referred for barium swallow to evaluate the upper GIT on account of clinical history of chronic dysphagia. Initial clinical work –up based on the patients’ symptom was equivocal in the distinction of oropharyngeal and esophageal dysphagia, thus justifying the need for a simple radiological procedure such as barium swallow. During the procedure, barium was visualized to have been aspirated into the lungs. The need to understand the patients underlying history, experience in performing the procedure and early recognition of the signs of aspiration are emphasized. It also underscores the need to exercise caution, especially in patient’s whose symptoms are equivocal, and when oropharyngeal dysphagia is suspected. The classical radiological appearances of barium pneumonitis, its implications and outcome are presented. Keywords: Barium, bronchogram, aspiration, pneumonitis. INTRODUCTION The evaluation of dysphagia in patients is a challenge al., 2007; Penington GR, 1994). In a review of over 300 commonly encountered in family practice, and its prior cases of Barium studies in our facility, no case of diagnosis, treatment and rehabilitation requires the barium aspiration was noted.
    [Show full text]
  • Town of Hanson Hazard Mitigation and Municipal Vulnerability
    Town of Whitman, Massachusetts Integrated Municipal Vulnerability Preparedness and Hazard Mitigation Plan (MVP-HMP) Community Resilience Building Workshop Summary of Findings Prepared by Old Colony Planning Council April 2021 1 | P a g e Acknowledgements This plan was prepared for the Town of Whitman by the Old Colony Planning Council (OCPC) under the direction of the Massachusetts Emergency Management Agency (MEMA) and the Massachusetts Executive Office of Energy and Environmental Affairs (EOEEA). The plan was funded by the Commonwealth’s Municipal Vulnerability Preparedness program. Old Colony Planning Council (OCPC) OCPC Officers President Christine Joy Treasurer Douglas Sylverstre Secretary Sandra Wright COMMUNITY DELEGATE ALTERNATE Abington Steven Santeusanio Avon Frank P. Staffier John Costa Bridgewater Sandra Wright Brockton Preston Huckabee, P.E. Duxbury Valarie Massard, AICP, CFM George D. Wadsworth East Bridgewater Peter Spagone, Jr. Easton Jeanmarie Kent Joyce Halifax Amy Troup Hanover Hanson Deborah Pettey Philip Lindquist Kingston Robert Downey Paul Basler Pembroke Rebecca Colleta Daniel Trabucco Plymouth Lee Hartmann, AICP Plympton Christine Joy James Mulcahy Stoughton Douglas Sylvestre Forrest Lindwall West Bridgewater Eldon F. Moreira Whitman Fred L. Gilmetti Dan Salvucci Delegate-at-Large Troy E. Garron OCPC Staff Mary Waldron Executive Director Charles Kilmer, AICP Assistant Director/Transportation Program Manager Shawn Bailey Senior Transportation Planner Lila Burgess Ombudsman Program Director Dottie Fulginiti Economic
    [Show full text]
  • Industrial Chemicals for BRC (No Konzo)
    ACMT MEDICAL TOXIOLOGY SUB-BOARD REVIEW COURSE: INDUSTRIAL TOXINS- DUSTS AND GASES Jeffrey Brent, M.D., Ph.D. Toxicology Associates University of Colorado School of Medicine And Colorado School of Public Health Occupational Exposure levels • OSHA PEL = an 8 hr TWA STEL/Ceil = 15 minute max • ACGIH TLV = TWAs– also 8 hr STEL Pneumoconioses • The accumulation of dusts in the lung and reactions, if any, to them • Radiographically evaluated by B- readers using ILO classification • CT more sensitive Which Pneumoconioses Are Fibrogenic? Fibrogenic dusts Non-fibrogenic dusts Silica (crystalline) Tin (stannosis) Mica Barium (baritosis) Graphite Iron (siderosis) Beryllium Coal dust Asbestos Talc Not all patients with pneumoconiosis from the above develop fibrosis What is this? Coal workers’ Pneumoconiosis “Black Lung” • Caused by iron in coal dust Types Simple coal workers pneumoconiosis CWP complicated by fibrosis Silicosis COPD • Pathognomonic lesion is the coal dust macule = coal dust filled macrophages • Smoking not a risk factor • Not an accepted risk factor for lung ca • Exposure limits based on amount of silica exposure What do you see in this slide? Asbestos • Natural hydrated magnesium silicate fibers • OSHA expresses the asbestos PEL as fibers/mm3 in air • All disease caused only by inhalation exposure • It is not systemically absorbed by any route but inhaled fibers can migrate Types of Asbestos Fibers 2 types 1. Serpentine (“white asbestos”) = chrysotile Fibers tend to be degraded after inhalation Curly fibers 2. Amphiboles (“brown asbestos”) 5 sub-types (most disease assoc. with crocidolite) Fibers resist degradation Tendency to migrate Straight fibers This is the form that causes mesothelioma Asbestos – Related Diseases • Only clearly established target organ is lung and surrounding tissues • All have long latencies 1.
    [Show full text]
  • Airborne Dust WHO/SDE/OEH/99.14 Chapter 1 - Dust: Definitions and Concepts
    Hazard Prevention and Control in the Work Environment: Airborne Dust WHO/SDE/OEH/99.14 Chapter 1 - Dust: Definitions and Concepts Airborne contaminants occur in the gaseous form (gases and vapours) or as aerosols. In scientific terminology, an aerosol is defined as a system of particles suspended in a gaseous medium, usually air in the context of occupational hygiene, is usually air. Aerosols may exist in the form of airborne dusts, sprays, mists, smokes and fumes. In the occupational setting, all these forms may be important because they relate to a wide range of occupational diseases. Airborne dusts are of particular concern because they are well known to be associated with classical widespread occupational lung diseases such as the pneumoconioses, as well as with systemic intoxications such as lead poisoning, especially at higher levels of exposure. But, in the modern era, there is also increasing interest in other dust-related diseases, such as cancer, asthma, allergic alveolitis, and irritation, as well as a whole range of non-respiratory illnesses, which may occur at much lower exposure levels. This document aims to help reduce the risk of these diseases by aiding better control of dust in the work environment. The first and fundamental step in the control of hazards is their recognition. The systematic approach to recognition is described in Chapter 4. But recognition requires a clear understanding of the nature, origin, mechanisms of generation and release and sources of the particles, as well as knowledge on the conditions of exposure and possible associated ill effects. This is essential to establish priorities for action and to select appropriate control strategies.
    [Show full text]